In the Claims:

Please cancel claims 17-20.

Please add claims 21-25 as follows:

Claims 1-20 (Cancelled)

21. (New) A transgenic mouse whose genome comprises a disruption in a serine protease gene comprising SEQ ID NO:1, wherein where the disruption is heterozygous, and wherein, upon breeding with a second transgenic mouse whose genome comprises a disruption in the serine protease gene comprising SEQ ID NO:1, the transgenic mouse produces a transgenic mouse having a homozygous disruption in the serine protease gene comprising SEQ ID NO:1 and exhibiting a lethality during embryonic development.

22. (New) The transgenic mouse of claim 21, wherein the lethality occurs between about 12.5 and 14.5 days of embryonic growth.

23. (New) A method of producing a transgenic mouse whose genome comprises a disruption in a serine protease gene comprising SEQ ID NO:1, the method comprising:

(a) providing a mouse embryonic stem cell comprising a disruption in the serine protease gene comprising SEQ ID NO:1;

(b) introducing the mouse embryonic stem cell into a mouse blastocyst;

(c) introducing the mouse blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and

(d) breeding two chimeric mice to produce the transgenic mouse,

wherein where the disruption is heterozygous, the transgenic mouse, upon breeding, produces a transgenic mouse whose genome comprises a homozygous disruption in the serine protease gene comprising SEQ ID NO:1 exhibiting a lethality during embryonic development.

24. (New) A transgenic mouse whose genome comprises a disruption in a serine protease gene comprising SEQ ID NO:1, wherein, where the disruption is homozygous, the transgenic mouse lacks functional expression of a serine protease encoded by the serine protease gene comprising SEQ ID NO:1 and exhibits a lethality during embryonic development.

25. (New) The transgenic mouse of claim 24, wherein the lethality occurs between about 12.5 and 14.5 days of embryonic growth.